Sarchi Christopher 4
4 · Replimune Group, Inc. · Filed Apr 6, 2026
Research Summary
AI-generated summary of this filing
Replimune (REPL) CCO Christopher Sarchi Sells 6,500 Shares
What Happened
Christopher Sarchi, Chief Commercial Officer of Replimune Group, sold 6,500 shares of REPL in an open-market/private sale on April 2, 2026. The weighted-average sale price was $8.01 (range $8.00–$8.06), for aggregate proceeds of approximately $52,065. This was a sale (not a purchase or option exercise).
Key Details
- Transaction date: 2026-04-02; Transaction type: Sale (S)
- Price: weighted average $8.01; reported range $8.00–$8.06 (report says per-price breakdown can be provided on request)
- Shares sold: 6,500; Proceeds: ~$52,065
- Holdings after sale: beneficial ownership of 151,588 shares (includes restricted stock units)
- Derivatives: holds options to acquire 250,425 shares, of which 142,555 are exercisable as of the report date
- Trading plan: sale executed under a Rule 10b5-1 trading plan adopted December 15, 2025 (footnote indicates plan compliance)
- Timeliness: Form 4 filed Apr 6, 2026 reporting a 4/2/2026 transaction; no late filing indicator shown
Context
Trades under a 10b5-1 plan are prearranged and do not necessarily reflect the insider’s current view of the company; they are commonly used for scheduled liquidity. This filing reports a routine insider sale rather than a purchase or option exercise; investors often treat purchases as stronger signals of insider conviction.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-04-02$8.01/sh−6,500$52,065→ 151,588 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.06. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Following the sales reported on this Form 4, the reporting person continues to beneficially own 151,588 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 250,425 shares of the Issuer's common stock, 142,555 of which are exercisable as of the date hereof.